# 冠状病毒疾病生物学和既往治疗努力


---


## 针对病毒或宿主生物系统和相关疫苗工作的SARS/MERS治疗药物列表。


该信息来自“冠状病毒——药物发现和治疗选择”(A. Zumla et al.,2016)综述文章的表2，该文章描述了SARS-CoV和MERS-CoV的基因组。


### 靶向病毒


| Targeted Viral components                          | Potential therapeutics |
| -------------------------------------------------- | ---------------------- |
| Nucleosides or Nucleotides                         | Mycophenolic Acid      |
| Base Sequence GUC in <br />loop region of CoV mRNA | Ribozyme               |
| Viral Replication complex                          | K22                    |
| Long Viral dsRNA                                   | DRACO                  |
| PLpro                                              | GRL0617                |
| 3CLpro                                             | Lopinavir              |
| RdRp                                               | Ribavirin, BCX4430,    |
| Helicase                                           | Bananins, SSYA10-001   |
| RBD of S1 Subunit of S protein                     | NERS-4, MERS-27        |
|S2 subunit of S                                     | HR2P and P1 peptides   |
|Oligosaccharides onS                                |  Griffithsin           |
|S expression|siRNA*|
|E | siRNA*, Hexamethylene amiloride|
|M | siRNA*|
|N | PJ34, intrabodies‡ and siRNA*|
|Accessory proteins| siRNA* |
|Lipid membrane| LJ001 and JL103|


### 目标主机


| Targeted host factors                  | Potential Therapeutics                                       |
| -------------------------------------- | ------------------------------------------------------------ |
| Interferon Response                    | Recombinant interferons(interferon alfa, interferon beta, interferon gamma), Poly(I:C), Nitazoxanide             |
| Cyclophilins                           | Cyclosporine, alisporivir                                    |
| Kinase signalling pathways             | Trametinib, selumetinib, everolimus, <br /> rapacycin, dasatinib, imatinib |
| ACE2                                   | P4 and P5 peptides, NAAE                                     |
| DPP4                                   | anti-DPP4 mAb                                                |
| Endosomal protease (cathepsins)        | E64D, K11777, small molecule 5705213                         |
| Surface Protease (TMPRSS2)             | Camostat mesylate                                            |
| Other host proteases (furin)           | dec-RVKR-CMK                                                 |
| Clathrin-mediated endocytosis (ATP1A1) | Chlorpromazine, Ouabain, bufalin                             |
| Endosomal acidification                | Chloroquine                                                  |


### 疫苗


| Vaccine Type                           | Examples                                                     |
| -------------------------------------- | ------------------------------------------------------------ |
| Live attenuated virus                  | rMERS‐CoV‐ΔE            |
| DNA plasmid                          | MERS‐CoV S DNA |
| Viral vectors            | MVA‐MERS‐S, Ad5‐MERS‐S, Ad5‐MERS‐S1, Ad5‐S and Ad41‐S |
| Nanoparticles                                  | MERS‐CoV S‐containing nanoparticles                   |
| Virus‐like particles                                   | VRP‐S                                         |
| Recombinant protein subunits       | S(RBD)‐Fc, S1(358–588)‐Fc, S(377–588)‐Fc and rRBD                 |






---


## 实验验证的冠状病毒-宿主相互作用列表


[PHISTO]提供了82种冠状病毒-人类相互作用与实验证据(http://www.phisto.org/)涉及33种人类蛋白和21种冠状病毒蛋白。


[数据下载](https://aidd-common.oss-cn-hangzhou.aliyuncs.com/file/Corona_human_interaction.csv)




<br>


{[English](https://ghddi-ailab.github.io/Targeting2019-nCoV/nCov_Targets), [中文](https://ghddi-ailab.github.io/Targeting2019-nCoV/CN_nCov_Targets/)}


上次更新：{{git_revision_date_localized}}
